Perspectives on Key Presentations in GI Cancer from ASCO-GI 2022: Part II

Rapid Reactions

Rapid Reactions is a video series that provides commentary from key experts summarizing data released at the 2022 American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO-GI) focused on gastric, gastroesophageal, and esophageal cancer. Please join Minsig Choi, MD, from Stonybrook University Cancer Center, as he discusses the following 3 pivotal presentations from ASCO-GI 2022:

  • Results of the GERCOR NEONIPIGA phase 2 study indicated that neoadjuvant therapy with nivolumab and ipilimumab was feasible and was associated with a high pathologic complete response rate in patients with microsatellite instability/DNA mismatch repair deficiency resectable esophagogastric junction and gastric adenocarcinoma
  • Findings of the phase 2 study of FOLFOX plus nab-paclitaxel indicated that the anthracycline-based triplet regimen was associated with a high response rate and expected toxicities in patients with metastatic or advanced unresectable gastric, gastroesophageal junction adenocarcinoma
  • Results of the Ni-HIGH study showed that the combination of nivolumab plus trastuzumab and either S-1 or capecitabine plus oxaliplatin was tolerable and demonstrated promising antitumor activity in chemotherapy-naïve patients with HER2-positive advanced gastric cancer

Read the Articles Discussed in the Video

  1. Neoadjuvant Nivolumab plus Ipilimumab and Adjuvant Nivolumab in Patients with Localized Microsatellite Instability-High/Mismatch Repair Deficient Gastric Adenocarcinoma: GERCOR NEONIPIGA
  2. FOLFOX plus FOLFOX-A in the Treatment of Metastatic or Advanced Unresectable Gastric/Gastroesophageal Junction Adenocarcinoma
  3. Nivolumab plus Trastuzumab with S-1/Capecitabine plus Oxaliplatin for HER2-Positive Advanced Gastric Cancer: The Ni-HIGH Study

Uncategorized - October 16, 2018

Biomarker-Guided Targeted and Checkpoint Inhibitor Therapy in Melanoma: Best Practices from the City of Hope Comprehensive Cancer Center

The target audience for this series includes physicians (medical and surgical oncologists, interventional radiologists), oncology nurse navigators, oncology nurses, pathologists, oncology pharmacists, and other stakeholders involved in delivering personalized care to cancer patients.

Uncategorized - January 5, 2016

Panobinostat: a Histone Deacetylase Inhibitor

In the cell nucleus, DNA is maintained in a tightly coiled state around proteins called histones.1 During the process of DNA replication for cell division or during the synthesis of RNA and proteins, histone ace­tyltransferase adds acetyl groups onto the histones, enabling DNA to uncoil.1 By contrast, histone deacetylases (HDACs) [ Read More ]